NCT04870944: CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 12 Months to 30 Years (Child, Adult)
Location of Metastases: Brain
Additional Notes: Breast cancer patients are eligible for part 1A
Exclusions: Patients older than 21 years of age

Comments are closed.

Up ↑